BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


View Clinical Trials from BioPharm Insight

Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

 Key Statistics

Ownership: Public

Web Site: Progenics Pharmaceuticals, Inc.
Symbol: PGNX

 Company News
Progenics Pharmaceuticals, Inc. (PGNX) Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer 2/26/2015 10:15:45 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present Full Phase 2 Data For PSMA ADC At The 2015 American Society of Clinical Oncology GU Symposium 2/24/2015 7:14:32 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present At The 2015 RBC Capital Markets' Healthcare Conference 2/18/2015 8:11:32 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/4/2015 7:47:20 AM
Progenics Pharmaceuticals, Inc. (PGNX) Relaunches Pivotal Trial Of AZEDRA™ In Pheochromocytoma 1/23/2015 7:29:51 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Presentation At Radiological Society of North America (RSNA) Annual Meeting 12/5/2014 10:45:41 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Participate In Upcoming Conferences 11/12/2014 10:08:23 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Third Quarter 2014 Financial Results 11/7/2014 8:42:43 AM
Progenics Pharmaceuticals, Inc. (PGNX) Sets Third Quarter Financial Results Call For November 7 10/27/2014 9:55:54 AM
Phase 2 Data For Progenics Pharmaceuticals, Inc. (PGNX)' 1404 Imaging Agent Presented At EANM Congress 10/20/2014 6:40:34 AM